Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$622K Sell
1,716
-1
-0.1% -$342 0.13% 74
2026
Q1
$604K Buy
1,717
+594
+53% +$212K 0.14% 68
2025
Q4
$368K Buy
1,123
+6
+0.5% +$1.9K 0.09% 82
2025
Q3
$315K Buy
1,117
+55
+5% +$16K 0.08% 89
2025
Q2
$297K Buy
1,062
+1
+0.1% +$283 0.09% 83
2025
Q1
$331K Sell
1,061
-13
-1% -$3.84K 0.15% 65
2024
Q4
$280K Sell
1,074
-24
-2% -$7.12K 0.13% 67
2024
Q3
$354K Buy
1,098
+53
+5% +$17.3K 0.18% 45
2024
Q2
$326K Buy
1,045
+1,002
+2,330% +$294K 0.2% 44
2024
Q1
$12.2K Buy
43
+7
+19% +$2.05K 0.01% 212
2023
Q4
$10.3K Buy
+36
New +$9.81K 0.01% 206

Other funds holding AMGN

Dunhill Financial's AMGN Position: Q2 2026 in Review

Dunhill Financial reduced its Amgen (AMGN) stake by 0.06% in Q2 2026, selling an estimated $342 and leaving 1,716 shares worth $622K. The position accounts for 0.13% of the portfolio, ranked #74.

Dunhill Financial first reported a position in AMGN in Q4 2023 and has held it in 11 quarters since. 3,139 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Dunhill Financial held 1,716 shares of Amgen worth $622K as of Q2 2026.
  • Dunhill Financial sold 1 Amgen share in Q2 2026, an estimated $342.
  • Amgen made up 0.13% of Dunhill Financial's portfolio in Q2 2026, its #74 holding.
  • Dunhill Financial first reported a position in Amgen in Q4 2023 and has held it in 11 quarters since.
  • 3,139 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.